Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by TheMadMonkon Nov 08, 2023 5:57pm
324 Views
Post# 35724779

H2O on the H2S

H2O on the H2SPlease, someone get a bucket of cold water and douse this red hot stock.   How is it that a few weeks ago all these complainers on various chat boards were crying that there is going to be dilution right after P2.  Now these same people are trying to bid up the price as quick and as high as possible so the we get diluted pre P2.  There are 3,118,000 warrants set to expire by the end of the year with a strike price of $1.80.  Why would anyone who truly believes this company is going to be successful with Otena, want to be diluted by nearly 6% at a measly $1.80 per share?  If management said that they were going to do a raise before the end of the year and sell more than three million shares sub two bucks, these boards would be loaded with "investors" calling for the heads of management.  Now they are all talking about "taking out the next wall" and driving the price higher.  If you truly believe in this drug/platform you would not sell before P2 or if you were a little more risk adverse you would wait until after P3.  Who cares what the price is before P2 even starts.  Hopefully the price stays below $1.80 until after the new year and we are not diluted at a lousy $100 million valuation.  Just my thoughts.
<< Previous
Bullboard Posts
Next >>